Chloroquine binding reveals flavin redox switch function of quinone reductase 2

Journal of Biological Chemistry

Volumn 288, Issue 16, 2013, Pages 11242-11251

  Leung, Kevin K K ^a   Shilton, Brian H ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BIOACTIVE MOLECULES; CELLULAR FUNCTION; FLAVOENZYMES; QUINONE REDUCTASE 2; REDOX SWITCH;

BIOCHEMISTRY;

BIOLOGY;

CHLOROQUINE; FLAVINE ADENINE NUCLEOTIDE; FLAVOPROTEIN; ISOALLOXAZINE; PRIMAQUINE; QUINONE REDUCTASE 2; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG BINDING; ENZYME BINDING; ENZYME CONFORMATION; HUMAN; OXIDATION; PRIORITY JOURNAL; PROTEIN FUNCTION; REDUCTION; X RAY CRYSTALLOGRAPHY;

BINDING SITES; CHLOROQUINE; CRYSTALLOGRAPHY, X-RAY; FLAVIN-ADENINE DINUCLEOTIDE; HUMANS; OXIDATION-REDUCTION; PROTEIN BINDING; PROTEIN STRUCTURE, SECONDARY; QUINONE REDUCTASES;

EID: 84876513000     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M113.457002     Document Type: Article

References (53)

1. Hill, D. R., Baird, J. K., Parise, M. E., Lewis, L. S., Ryan, E. T., and Magill, A. J. (2006) Primaquine. Report from CDC expert meeting on malaria chemoprophylaxis I. Am. J. Trop. Med. Hyg. 75, 402-415.
2. Lalloo, D. G., Shingadia, D., Pasvol, G., Chiodini, P. L., Whitty, C. J., Beeching, N. J., Hill, D. R., Warrell, D. A., Bannister, B. A., and HPA Advisory Committee on Malaria Prevention in UK Travellers (2007) UK malaria treatment guidelines. J. Infect. 54, 111-121.
3. Foley, M., and Tilley, L. (1998) Quinoline antimalarials. Mechanisms of action and resistance and prospects for new agents. Pharmacol. Ther. 79, 55-87.
4. Fitch, C. D. (2004) Ferriprotoporphyrin IX, phospholipids, and the antimalarial actions of quinoline drugs. Life Sci. 74, 1957-1972.
5. Vale, N., Moreira, R., and Gomes, P. (2009) Primaquine revisited six decades after its discovery. Eur. J. Med. Chem. 44, 937-953.
6. Graves, P. R., Kwiek, J. J., Fadden, P., Ray, R., Hardeman, K., Coley, A. M., Foley, M., and Haystead, T. A. (2002) Discovery of novel targets of quinoline drugs in the human purine binding proteome. Mol. Pharmacol. 62, 1364-1372.
7. Benfield, T., Atzori, C., Miller, R. F., and Helweg-Larsen, J. (2008) Secondline salvage treatment of AIDS-associated Pneumocystis jirovecii pneumonia. A case series and systematic review. J. Acquir. Immune Defic. Syndr. 48, 63-67.
8. Berman, J. D., and Lee, L. S. (1984) Activity of antileishmanial agents against amastigotes in human monocyte-derived macrophages and in mouse peritoneal macrophages. J. Parasitol. 70, 220-225.
9. Kinnamon, K. E., Poon, B. T., Hanson, W. L., and Waits, V. B. (1996) Primaquine analogues that are potent anti-Trypanosoma cruzi agents in a mouse model. Ann. Trop. Med. Parasitol. 90, 467-474.
10. Wallace, D. J., Gudsoorkar, V. S., Weisman, M. H., and Venuturupalli, S. R. (2012)Newinsights into mechanisms of therapeutic effects of antimalarial agents in SLE. Nat. Rev. Rheumatol. 8, 522-533.
11. Solomon, V. R., and Lee, H. (2009) Chloroquine and its analogs: a new promise of an old drug for effective and safe cancer therapies. Eur. J. Pharmacol. 625, 220-233.
12. Savarino, A., Boelaert, J. R., Cassone, A., Majori, G., and Cauda, R. (2003) Effects of chloroquine on viral infections. An old drug against today's diseases? Lancet Infect. Dis. 3, 722-727.
13. Rix, U., Hantschel, O., Dürnberger, G., Remsing Rix, L. L., Planyavsky, M., Fernbach, N. V., Kaupe, I., Bennett, K. L., Valent, P., Colinge, J., Köcher, T., and Superti-Furga, G. (2007) Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood 110, 4055-4063.
14. Winger, J. A., Hantschel, O., Superti-Furga, G., and Kuriyan, J. (2009) The structure of the leukemia drug imatinib bound to human quinone reductase 2 (NQO2). BMC Struct. Biol. 9, 7.
15. Duncan, J. S., Gyenis, L., Lenehan, J., Bretner, M., Graves, L. M., Haystead, T. A., and Litchfield, D. W. (2008) An unbiased evaluation of CK2 inhibitors by chemoproteomics. Characterization of inhibitor effects on CK2 and identification of novel inhibitor targets. Mol. Cell. Proteomics 7, 1077-1088.
16. Brehmer, D., Godl, K., Zech, B., Wissing, J., and Daub, H. (2004) Proteome-wide identification of cellular targets affected by bisindolylmaleimide-type protein kinase C inhibitors. Mol. Cell. Proteomics 3, 490-500.
17. Buryanovskyy, L., Fu, Y., Boyd, M., Ma, Y., Hsieh, T. C., Wu, J. M., and Zhang, Z. (2004) Crystal structure of quinone reductase 2 in complex with resveratrol. Biochemistry 43, 11417-11426.
18. Mailliet, F., Ferry, G., Vella, F., Berger, S., Cogé, F., Chomarat, P., Mallet, C., Guénin, S.-P., Guillaumet, G., Viaud-Massuard, M.-C., Yous, S., Delagrange, P., and Boutin, J. A. (2005) Characterization of the melatoninergic MT3 binding site on the NRH:quinone oxidoreductase 2 enzyme. Biochem. Pharmacol. 71, 74-88.
19. Calamini, B., Santarsiero, B. D., Boutin, J. A., and Mesecar, A. D. (2008) Kinetic, thermodynamic and X-ray structural insights into the interaction of melatonin and analogues with quinone reductase 2. Biochem. J. 413, 81-91.
20. Vella, F., Ferry, G., Delagrange, P., and Boutin, J. A. (2005) NRH:quinone reductase 2. An enzyme of surprises and mysteries. Biochem. Pharmacol. 71, 1-12.
21. Bogan, K. L., and Brenner, C. (2008) Nicotinic acid, nicotinamide, and nicotinamide riboside. A molecular evaluation of NAD+ precursor vita-mins in human nutrition. Annu. Rev. Nutr. 28, 115-130.
22. Gong, X., Kole, L., Iskander, K., and Jaiswal, A. K. (2007) NRH:quinone oxidoreductase 2 and NAD(P)H:quinone oxidoreductase 1 protect tumor suppressor p53 against 20s proteasomal degradation leading to stabilization and activation of p53. Cancer Res. 67, 5380-5388.
23. Khutornenko, A. A., Roudko, V. V., Chernyak, B. V., Vartapetian, A. B., Chumakov, P. M., and Evstafieva, A. G. (2010) Pyrimidine biosynthesis links mitochondrial respiration to the p53 pathway. Proc. Natl. Acad. Sci. U.S.A. 107, 12828-12833.
24. Reybier, K., Perio, P., Ferry, G., Bouajila, J., Delagrange, P., Boutin, J. A., and Nepveu, F. (2011) Insights into the redox cycle of human quinone reductase 2. Free Radic. Res. 45, 1184-1195.
25. Kwiek, J. J., Haystead, T. A., and Rudolph, J. (2004) Kinetic mechanism of quinone oxidoreductase 2 and its inhibition by the antimalarial quinolines. Biochemistry 43, 4538-4547.
26. Becker, D. F., Zhu, W., and Moxley, M. A. (2011) Flavin redox switching of protein functions. Antioxid. Redox Signal. 14, 1079-1091.
27. Leung, K. K., Litchfield, D. W., and Shilton, B. H. (2012) Flavin adenine dinucleotide content of quinone reductase 2. Analysis and optimization for structure-function studies. Anal. Biochem. 420, 84-89.
28. Kabsch, W. (2010) XDS. Acta Crystallogr. D Biol. Crystallogr. 66, 125-132.
29. Leslie, A. G. W., and Powell, H. R. (2007) Processing diffraction data with Mosflm. Evolving Methods Macromol. Crystallogr. 245, 41-51.
30. Evans, P. (2006) Scaling and assessment of data quality. Acta Crystallogr.D Biol. Crystallogr. 62, 72-82.
31. Foster, C. E., Bianchet, M. A., Talalay, P., Zhao, Q., and Amzel, L. M. (1999) Crystal structure of human quinone reductase type 2, a metalloflavoprotein. Biochemistry 38, 9881-9886.
32. Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L. W., Kapral, G. J., Grosse-Kunstleve, R. W., Mc-Coy, A. J., Moriarty, N. W., Oeffner, R., Read, R. J., Richardson, D. C., Richardson, J. S., Terwilliger, T. C., and Zwart, P. H. (2010) PHENIX. A comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D Biol. Crystallogr. 66, 213-221.
33. Rubin, J. R., Swaminathan, P., and Sundaralingam, M. (1992) Structure of the anti-malarial drug primaquine diphosphate. Acta Crystallogr. C 48, 379-382.
34. Karle, J. M., and Karle, I. L. (1988) Redetermination of the crystal and molecular structure of the antimalarial chloroquine bis(dihydrogenphosphate) dihydrate. Acta Crystallogr. C 44, 1605-1608.
35. Clark, W. M., and Lowe, H. J. (1956) Studies on oxidation-reduction. XXIV. Oxidation-reduction potentials of flavin adenine dinucleotide. J. Biol. Chem. 221, 983-992.
36. Levitt, M., and Perutz, M. F. (1988) Aromatic rings act as hydrogen bond acceptors. J. Mol. Biol. 201, 751-754.
37. Hemmerich, P., Nagelschneider, G., and Veeger, C. (1970) Chemistry and molecular biology of flavins and flavoproteins. FEBS Lett. 8, 69-83.
38. Lange, N. A. (1999) Lange's Handbook of Chemistry, 15th Ed. (Dean, J. A., ed), p. 8.29, McGraw-Hill, Inc., New York.
39. Sollner, S., Schober, M., Wagner, A., Prem, A., Lorkova, L., Palfey, B. A., Groll, M., and Macheroux, P. (2009) Quinone reductase acts as a redox switch of the 20S yeast proteasome. EMBO Rep. 10, 65-70.
40. Sollner, S., Deller, S., Macheroux, P., and Palfey, B. A. (2009) Mechanism of flavin reduction and oxidation in the redox-sensing quinone reductase Lot6p from Saccharomyces cerevisiae. Biochemistry 48, 8636-8643.
41. Zoltowski, B. D., Schwerdtfeger, C., Widom, J., Loros, J. J., Bilwes, A. M., Dunlap, J. C., and Crane, B. R. (2007) Conformational switching in the fungal light sensor Vivid. Science 316, 1054-1057.
42. Möglich, A., and Moffat, K. (2007) Structural basis for light-dependent signaling in the dimeric LOV domain of the photosensor YtvA. J. Mol. Biol. 373, 112-126.
43. Long, D. J., 2nd, Iskander, K., Gaikwad, A., Arin, M., Roop, D. R., Knox, R., Barrios, R., and Jaiswal, A. K. (2002) Disruption of dihydronicotinamide riboside:quinone oxidoreductase 2 (NQO2) leads to myeloid hyperplasia of bone marrow and decreased sensitivity to menadione toxicity. J. Biol. Chem. 277, 46131-46139.
44. Ahn, K. S., Gong, X., Sethi, G., Chaturvedi, M. M., Jaiswal, A. K., and Aggarwal, B. B. (2007) Deficiency of NRH:quinone oxidoreductase 2 differentially regulates TNF signaling in keratinocytes. Up-regulation of apoptosis correlates with down-regulation of cell survival kinases. Cancer Res. 67, 10004-10011.
45. Yu, K.-D., Di, G.-H., Yuan, W.-T., Fan, L., Wu, J., Hu, Z., Shen, Z.-Z., Zheng, Y., Huang, W., and Shao, Z.-M. (2009) Functional polymorphisms, altered gene expression and genetic association link NRH:quinone oxidoreductase 2 to breast cancer with wild-type p53. Hum. Mol. Genet. 18, 2502-2517.
46. Rubinsztein, D. C., Codogno, P., and Levine, B. (2012) Autophagy modulation as a potential therapeutic target for diverse diseases. Nat. Rev. Drug Discov. 11, 709-730.
47. He, Y., Xu, Y., Zhang, C., Gao, X., Dykema, K. J., Martin, K. R., Ke, J., Hudson, E. A, Khoo, S. K., Resau, J. H., Alberts, A. S., MacKeigan, J. P., Furge, K. A., and Xu, H. E. (2011) Identification of a lysosomal pathway that modulates glucocorticoid signaling and the inflammatory response. Sci. Signal. 4, ra44.
48. Kim, E. L., Wüstenberg, R., Rübsam, A., Schmitz-Salue, C., Warnecke, G., Bücker, E.-M., Pettkus, N., Speidel, D., Rohde, V., Schulz-Schaeffer, W., Deppert, W., and Giese, A. (2010) Chloroquine activates the p53 pathway and induces apoptosis in human glioma cells. Neuro-Oncology 12, 389-400.
49. Asher, G., Lotem, J., Cohen, B., Sachs, L., and Shaul, Y. (2001) Regulation of p53 stability and p53-dependent apoptosis by NADH quinone oxidoreductase 1. Proc. Natl. Acad. Sci. U.S.A. 98, 1188-1193.
50. Asher, G., and Shaul, Y. (2005) p53 proteasomal degradation. Poly-ubiquitination is not the whole story. Cell Cycle 4, 1015-1018.
51. Vasiliou, V., Ross, D., and Nebert, D. W. (2006) Update of the NAD(P)H: quinone oxidoreductase (NQO) gene family. Hum. Genomics 2, 329-335.
52. Sollner, S., and Macheroux, P. (2009) New roles of flavoproteins in molecular cell biology. An unexpected role for quinone reductases as regulators of proteasomal degradation. FEBS J. 276, 4313-4324.
53. Laskowski, R. A., MacArthur, M., Moss, D. S., and Thornton, J. M. (1993) PROCHECK. A program to check the stereochemical quality of protein structures. J. Appl. Cryst. 26, 283-291.